A - Agilent Technologies, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
89.88
+1.20 (+1.35%)
As of 1:24PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close88.68
Open89.02
Bid90.04 x 1200
Ask90.07 x 1800
Day's Range89.02 - 90.61
52 Week Range61.13 - 93.04
Volume469,664
Avg. Volume2,031,327
Market Cap27.753B
Beta (5Y Monthly)1.12
PE Ratio (TTM)41.25
EPS (TTM)2.18
Earnings DateAug 12, 2020 - Aug 17, 2020
Forward Dividend & Yield0.72 (0.81%)
Ex-Dividend DateJun 29, 2020
1y Target Est90.17
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-3% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Barrons.com

    The 100 Most Sustainable Companies, Reranked by Social Factors

    Barron’s revisits its annual ESG ranking of the 100 most sustainable companies to focus on social issues.

  • Agilent (A) Up 9.9% Since Last Earnings Report: Can It Continue?
    Zacks

    Agilent (A) Up 9.9% Since Last Earnings Report: Can It Continue?

    Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Billions or trillions: The great coronavirus trade-off
    Yahoo Finance Video

    Billions or trillions: The great coronavirus trade-off

    Yahoo Finance’s Alexis Christoforous, Brian Sozzi, and Andy Serwer discuss the cost of developing a COVID-19 vaccine in such a short time, and why that money is worthwhile.

  • Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West
    Zacks

    Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West

    Zacks.com featured highlights include: Lowes Companies, Charles River Laboratories International, Agilent Technologies and East West

  • 4 GARP Stocks to Scoop Up for Maximum Returns
    Zacks

    4 GARP Stocks to Scoop Up for Maximum Returns

    If you're looking for a profitable portfolio of stocks that will offer the best of value and growth investing, try the growth at a reasonable price or GARP strategy.

  • Agilent Technologies Could Trade Still Higher in the Weeks Ahead
    TheStreet.com

    Agilent Technologies Could Trade Still Higher in the Weeks Ahead

    Agilent Technologies has broken out to a new all-time high. What chart points are now important for this leader in life sciences, diagnostics and applied chemical markets? Let's check. In this daily bar chart of A, below, we can see that prices have rallied 50% from their March low and have made new highs above the January peak.

  • Agilent (A) Launches Two Products in Mass Spectrometry
    Zacks

    Agilent (A) Launches Two Products in Mass Spectrometry

    Agilent (A) recently announces the launch of two products in a bid to expand presence in the Mass Spectrometry market.

  • Agilent Technologies Inc. (A): Are Hedge Funds Right About This Stock?
    Insider Monkey

    Agilent Technologies Inc. (A): Are Hedge Funds Right About This Stock?

    In this article you are going to find out whether hedge funds think Agilent Technologies Inc. (NYSE:A) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

  • Agilent's Shares March Higher, Can It Continue?
    Zacks

    Agilent's Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Agilent Technologies.

  • Agilent (A) Announces Proposed Offering of Senior Notes
    Zacks

    Agilent (A) Announces Proposed Offering of Senior Notes

    Agilent (A) plans to offer a series of senior notes, subject to market conditions and other factors.

  • Agilent Technologies Announces Pricing of $500 Million of Senior Notes
    Business Wire

    Agilent Technologies Announces Pricing of $500 Million of Senior Notes

    Agilent announces pricing of $500 million of senior notes.

  • Moody's

    Agilent Technologies, Inc. -- Moody's assigns Baa2 rating to Agilent's notes offering

    Moody's Investors Service, ("Moody's") assigned a Baa2 rating to the proposed offering of senior unsecured notes of Agilent Technologies, Inc. ("Agilent"). There are no changes to Moody's existing ratings of Agilent including the Baa2 senior unsecured long-term rating and the Prime-2 commercial paper rating. Proceeds of the offering will be used for general corporate purposes, including the repayment of indebtedness which may include Agilent's $500 million term loan maturing in August 2020.

  • MarketWatch

    Agilent files for an offering of senior notes

    Agilent Technologies Inc. said Monday it is offering a series of senior notes in a shelf registration with plans to use any proceeds for general corporate purposes, including to pay down debt. The company did not offer any detail on size or maturities. BofA Securities, Mizuho Securities USA LLC and Wells Fargo Securities, LLC are acting as joint book-running managers. Shares of the life sciences company were slightly lower premarket and have lost 3.3% in the year to date, while the S&P 500 has fallen 6%.

  • Agilent Technologies Announces Proposed Offering of Senior Notes
    Business Wire

    Agilent Technologies Announces Proposed Offering of Senior Notes

    Agilent announces proposed offering of senior notes.

  • Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot
    Business Wire

    Agilent Announces New Mass Spectrometry Products at ASMS 2020 Reboot

    Agilent Technologies Inc. (NYSE: A) today announced two new mass spectrometry (MS) products: the Agilent 6470B Triple Quadrupole LC/MS (6470 LC/TQ) system, and the Agilent RapidFire 400 system. Both deliver even faster detection of target compounds providing customers increased sample throughput and reduced time to generate results. The instruments are being introduced at ASMS 2020 Reboot, the interactive, online version of the annual conference of the American Society for Mass Spectrometry, being held June 1-12, 2020.

  • Barrons.com

    Recent Stock Rally May Trip Up Activist Investors

    This season has been more subtle than previous years, as the coronavirus pandemic has slowed campaigns. Many assumed that investors would quietly increase stakes. But while the broader market still trades below February highs, many sectors aren’t exactly cheap.

  • Why hedge-fund manager Bill Ackman says he dumped Berkshire Hathaway but held on to these winners
    MarketWatch

    Why hedge-fund manager Bill Ackman says he dumped Berkshire Hathaway but held on to these winners

    Pershing Square Capital Management hedge-fund manager Bill Ackman told investors on a call on Wednesday that he is dumping Warren Buffett’s Berkshire Hathaway. The stocks he bought more of and is keeping are worth paying attention to.

  • Billionaire Ackman Exits Berkshire Hathaway, Blackstone To Fund Opportunities
    SmarterAnalyst

    Billionaire Ackman Exits Berkshire Hathaway, Blackstone To Fund Opportunities

    Billionaire hedge fund manager Bill Ackman said that his Pershing Square Capital Management Ltd. has exited investments in Warren Buffett’s Berkshire Hathaway, the Blackstone Group Inc. (BX) and Park Hotels & Resorts (PK).Pershing Square’s stock holding in Berkshire was valued at about $1 billion as of the end of March. Ackman divested the Blackstone position as shares have soared about 57% over the past two months, erasing all of their losses from earlier this year.Despite strong stock market volatility triggered by the coronavirus pandemic, Pershing’s portfolio this year returned 27% on its investments as of May 26.Speaking on an investor conference call, Ackman said that Pershing Square has about 85% to 98% of its assets invested in its funds and is holding cash positions of between 15% and 20%.“We think it's a very different environment than when we made the investment in Berkshire a year ago”, said partner Ryan Israel, who oversaw Pershing’s Berkshire investment, on the investor call. “We continue to think Berkshire will be a strong investment over the longer term, but we also think the current environment means there may be more than typical opportunities for us to see very high-returning investments and we wanted to make sure we have enough cash.”At the beginning of the year, Ackman moved to protect the firm’s stock portfolio against coronavirus-related panic selling in markets by buying credit default swaps. Pershing Square yielded a stellar $2.6 billion from hedging its stock portfolio through the credit protection.Ackman said that today, “we have $10 billion of capital to invest; we can be much more nimble," adding that he wants to “take advantage of that nimbleness, preserve some extra liquidity in the event that prices get more attractive again."The billionaire investor informed investors that Pershing increased its positions in Agilent Technologies Inc. (A) by 16% at an average price of $64.57, while the stock is now trading at $86.18 a share. He also ramped up the portfolio’s stakes in Lowes Companies (LOW) at $84 a share (now trades at $128 a share), Howard Hughes, Restaurant Brands International (QSR), as well as rebuilt the Starbucks position at $60 a share. Shares in the coffee chain are currently trading at $78.60.“So far so good,” Ackman said. “Everything we currently own is undervalued.”Some analysts view Blackstone as a worthwhile investment. CFRA recently upgraded Blackstone to Buy from Hold, citing the company’s attractive valuation. “We view positively the secular growth opportunities at Blackstone, evidenced by 2019 asset inflows that topped $134 billion” CFRA said.“Though near-term results could be uneven amid market uncertainty and volatility, demand for private-equity investments will be fueled by the persistently low interest-rate environment” the firm explained, adding that Blackstone is also poised to deploy its more than $150 billion of unallocated capital in a marketplace where asset values have become more attractive.Shares in Blackstone rose less than 1% to $56.46 as of Wednesday’s close.Turning now to the Street’s outlook on Blackstone stock, TipRanks data shows that Wall Street analysts are still cautiously optimistic. The Moderate Buy consensus consists of 8 Buy and 4 Hold ratings. However, in view of the recent share rally, the $53.85 average price target now implies 4.6% downside potential over the coming year. (See Blackstone stock analysis on TipRanks).Related News: Gates Foundation Buys Up Amazon, Apple, Twitter Stock; Trims Berkshire Hathaway Stake Billionaire Ackman Takes New Bet On Blackstone, Trims Chipotle Stake Buffett’s Berkshire Shaves Off 84% Of Its Goldman Sachs Stake More recent articles from Smarter Analyst: * Emergent Bio Plunges 14% Post-Market After Directors Divest Shares * AbbVie Announces Partnership To Develop Novel Covid-19 Antibody Therapy * PG&E; Is Said To Ready $11 Billion Debt Financing Plan * Teva Wins Court Ruling Against Opiant, Emergent Bio On Narcan Nasal Spray

  • Agilent to Present at Jefferies Virtual Healthcare Conference
    Business Wire

    Agilent to Present at Jefferies Virtual Healthcare Conference

    Agilent to present at Jefferies Virtual Healthcare Conference.

  • Agilent Up 5% On Solid Revenue Beat, But Top Analysts Stay Cautious
    SmarterAnalyst

    Agilent Up 5% On Solid Revenue Beat, But Top Analysts Stay Cautious

    Shares in Agilent Technologies (A) rose 5% on Friday after the company reported revenue of $1.24B which beat Street estimates by $40M and came in flat on a year-over-year (y/y) basis.Q2 Non-GAAP EPS of $0.71 beat consensus by $0.10, although GAAP EPS of $0.32 misses by $0.17. The stock is now down 0.4% since the beginning of the year.Operating profit rose 2.2% y/y to $277M, while core revenue declined 1.7% y/y, reflecting the impact of Covid-19 business disruption (particularly within academic & government and chemical & energy end-markets).“Our business was tracking well into late March when we experienced significant disruption in the U.S. and Europe as customers closed or restricted access to their facilities to slow the spread of COVID-19,” said Mike McMullen, Agilent president and CEO.“I believe we are well-positioned to face the challenges brought on by COVID-19 given our focus on growth, a resilient business model, a strong balance sheet, and most importantly, our outstanding team” he added.Following earnings, Needham’s Stephen Unger reiterated his Hold rating without a price target. “Considering the COVID-19 environment, A’s FY2Q20 results were solid with adj. EPS growing 0.6% y/y to $0.71 – $0.04 below our model” he wrote.As a result, the analyst lowered his FY20 adj. EPS estimate from $3.42 to $3.02 (3% decline from FY19) on revenues of $5.122B (1.8% core revenue decline), a $388M reduction from his previous forecast.“Given increased downside potential associated with business disruption from the COVID-19 pandemic, we consider the lower half of the [stock’s current] trading range to approximate fair value ($79.00-89.00)” Unger told investors on May 22.Indeed, the majority of analysts covering A rate the stock a hold, with 7 recent hold ratings vs 4 buy ratings. The $89 average analyst price target indicates upside potential of 5%.  (See Agilent stock analysis on TipRanks)Related News: Gilead and Galapagos Score Positive Topline Results For Ulcerative Colitis Trial Moderna Spikes 21% Amid “Positive” Early-Stage Covid-19 Vaccine Data AstraZeneca-Merck Lynparza Prostate Cancer Treatment Gets FDA Approval More recent articles from Smarter Analyst: * Eli Lilly Starts Dosing Patients In World’s First Covid-19 Antibody Trial * Drugmaker Abbvie Teams Up With Jacobio To Develop Cancer Inhibitor * Immutep Surges In Pre-Market On Positive Efti Cancer Data * KKR Joins $3.3 Billion Bid To Acquire Spanish Telecom Carrier Masmovil

  • Coronavirus update: U.S. death toll approaches 100,000 as CDC’s testing practices are criticized by health experts
    MarketWatch

    Coronavirus update: U.S. death toll approaches 100,000 as CDC’s testing practices are criticized by health experts

    The U.S. death toll from the coronavirus that causes COVID-19 edged closer to 100,000 on Friday, as the news emerged that the Centers for Disease Control and Prevention has been combining the results of two different types of tests for the illness in a move that has been sharply criticized by health experts.

  • Thomson Reuters StreetEvents

    Edited Transcript of A earnings conference call or presentation 21-May-20 8:30pm GMT

    Q2 2020 Agilent Technologies Inc Earnings Call

  • Agilent's (A) Q2 Earnings Beat Estimates, Revenues Down Y/Y
    Zacks

    Agilent's (A) Q2 Earnings Beat Estimates, Revenues Down Y/Y

    Agilent's (A) second-quarter fiscal 2020 results reflect negative impact of coronavirus outbreak despite robust performance of the Diagnostics and Genomics Group.

  • Agilent Technologies Inc (A) Q2 2020 Earnings Call Transcript
    Motley Fool

    Agilent Technologies Inc (A) Q2 2020 Earnings Call Transcript

    Thank you, Jodi, and welcome everyone to Agilent's conference call for the second quarter of fiscal year 2020. On the webcast today are Mike McMullen, Agilent's President and CEO; and Bob McMahon, Agilent's Senior Vice President and CFO. Joining for the Q&A after prepared remarks will be Jacob Thaysen, President of Agilent's Life Science and Applied Markets Group; and Sam Raha, President of Agilent's Diagnostics and Genomics Group, along with Padraig McDonnell, President of the Agilent CrossLab Group.